证券代码：000597 证券简称：东北制药 公告编号：2026-006 | 产品开发、技术咨询服务、成果转让； | 专用化学产品销售（不含危险化学 | | --- | --- | | 污水处理、环保技术服务、环保技术 | 品）；化工产品生产（不含许可类化 | | 咨询；金属材料销售；厂房、设备租 | 工产品）；化工产品销售（不含许可 | | 赁，自营和代理各类商品和技术的进 | 类化工产品）；化妆品零售；化妆品 | | 出口；包装材料制造和销售；但国家 | 批发；技术服务、技术开发、技术咨 | | 限定公司经营或禁止进出口的商品 | 询、技术交流、技术转让、技术推广； | | 和技术除外。 | 环保咨询服务；医学研究和试验发展； | | | 污水处理及其再生利用；金属材料销 | | | 售；非居住房地产租赁；机械设备租 | | | 赁；小微型客车租赁经营服务；办公 | | | 设备租赁服务；特种设备出租；医用 | | | 包装材料制造；包装材料及制品销售； | | | 货物进出口；技术进出口；食品进出 | | | 口；食品销售（仅销售预包装食品）； | | | 食品互联网销售（仅销售预包装食 | | | 品） ...

证券代码：000597 证券简称：东北制药 公告编号：2026-009 东北制药集团股份有限公司关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东会届次：2026 年第一次临时股东会 2.股东会的召集人：董事会 2026 年 2 月 13 日，东北制药集团股份有限公司（以下简称"公司"）第十 届董事会第九次会议，以同意 11 票，反对 0 票，弃权 0 票，审议通过了《关于召 开公司 2026 年第一次临时股东会的议案》。 3.会议召开的合法、合规性：本次会议的召集、召开符合《中华人民共和国 公司法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第1号——主板上市公司规范运作》等法律、行政法规、部门规章、规范性文 件及《公司章程》的有关规定。 4.会议时间： （1）现场会议时间：2026 年 3 月 4 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 3 月 4 日 9:15-9:25，9:30-11:30，13: ...

证券代码：000597 证券简称：东北制药 公告编号：2026-004 东北制药集团股份有限公司 第十届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 1.东北制药集团股份有限公司（以下简称"公司"）第十届董事会第九次会 议于 2026 年 2 月 8 日发出会议通知，于 2026 年 2 月 13 日以通讯表决的方式召 开。 2.会议应参加董事 11 人，实际参加董事 11 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 二、董事会会议审议情况 会议审议并以记名投票表决方式通过以下议案： 议案一：关于 2026 年度日常关联交易预计的议案 具体内容详见公司披露于巨潮资讯网的《东北制药集团股份有限公司关于 2026 年度日常关联交易预计的公告》（公告编号：2026-005）。 关联董事郭建民先生、黄成仁先生、敖新华先生、黄智华先生回避表决。 表决结果：同意 7 票，反对 0 票，弃权 0 票，回避 4 票 ...

（记者 张明双） 每经AI快讯，东北制药2月13日晚间发布公告称，公司第十届第九次董事会会议于2026年2月13日以通 讯表决的方式召开。会议审议了《关于2026年度日常关联交易预计的议案》等文件。 每经头条（nbdtoutiao）——上市公司净利从暴增9倍到突然预亏超2亿元，董事长为何自掏5000万元补 窟窿？50亿元信托理财也去向成谜，股民直呼看不懂 ...

Core Viewpoint - Northeast Pharmaceutical is implementing a "one body, two wings" development strategy to enhance resilience and profitability amid industry challenges and market competition [1] Group 1: Operational Efficiency and Market Strategy - The company is focusing on improving operational quality and market expansion, with a steady increase in core business foundations [2] - By 2025, the company aims for multiple breakthroughs in market layout, with core products achieving historical sales highs and brand influence steadily increasing [2] - The raw materials segment is adapting to market fluctuations by optimizing sales structures and expanding into emerging fields, solidifying its market position [2] Group 2: Production and Quality Control - Northeast Pharmaceutical has achieved cost reduction and efficiency improvements while maintaining a 100% product pass rate for factory output and inspections [3] - The company is enhancing production efficiency through process optimization, equipment upgrades, and management improvements [3] Group 3: Research and Innovation - The company is driving growth through both generic and innovative drugs, with three new generic products approved for market by March 2025 [3] - Ongoing projects in biopharmaceuticals and health products are being developed, including new health-oriented products like functional skincare items [3] Group 4: Strategic Development Framework - The "one body, two wings" strategy aims to strengthen the core business of chemical generics while expanding into biopharmaceuticals and traditional Chinese medicine [4] - The company plans to enhance its competitive advantage and market influence across all business segments, focusing on key product sales and overseas promotion of certified products [4] Group 5: Support Systems for Strategy Implementation - To ensure the effective implementation of the "one body, two wings" strategy, the company is optimizing management mechanisms and enhancing operational efficiency [5] - The focus is on risk management, cost control, and digital transformation to improve overall business quality [5] Group 6: Future Growth Drivers - The core growth drivers for the company include the successful transformation of innovative research results and the internationalization of the raw materials business [6] - Digital management and efficiency improvements are also seen as positive factors for driving performance growth [6]

● 本报记者 宋维东 东北制药相关负责人日前在接受中国证券报记者采访时表示，面对行业调整、市场竞争加剧等多重挑 战，公司将锚定"一体两翼"发展战略，坚持稳健经营与创新突破并举，深耕医药核心主业，拓展多元赛 道，打造更多盈利增长点，持续增强发展韧性。 运营质效持续提升 "在药品集采常态化、医保改革持续深化、行业竞争日趋激烈的背景下，东北制药紧扣'变、干、实'工 作总要求，主动适应行业变革，在经营提质、市场拓展、生产增效、研发创新等方面协同发力，发展质 效稳步提升，核心业务根基持续夯实。"该负责人说。 2025年，公司市场布局多点突破，营销效能持续释放。其中，制剂板块聚焦核心产品，深耕终端市场， 渠道覆盖与市场渗透力不断增强，多款主导产品销量创历史新高，新开发终端与主要品种覆盖率均同比 增长，品牌影响力稳步提升。此外，原料药板块积极应对国内外市场波动，通过优化产品销售结构、拓 展新兴领域等举措，核心产品市场地位不断稳固，海外市场持续拓展。该负责人表示，公司各子公司协 同发力，部分子公司成功扭亏为盈，构筑起多元协同、稳健向好的发展格局。 在生产运营方面，东北制药实现降本增效与质量管控双线提升。公司构建了"产销协同、 ...

证券代码：000597 证券简称：东北制药 公告编号：2026-003 东北制药集团股份有限公司 4.对上市公司损益产生的影响：2,792.5 万元已计入东北制药集团股份有限 公司（以下简称"东北制药"或"公司"）2024 年度损益，案件受理费及执行费 合计 45.85 万元，预计会减少公司 2025 年度损益，最终金额及会计处理以审计机 构年度审计结果为准。 一、本次诉讼事项的基本情况 公司于近日收到内蒙古自治区高级人民法院《民事裁定书》（2025）内民申 1122 号。 再审申请人北京华德停车场管理有限公司（以下简称"北京华德"）、公司 与被申请人东药乌海化工有限公司（以下简称"乌海化工"）及一审第三人乌海 市海南区双清农牧业开发有限责任公司（以下简称"乌海双清"）合同纠纷一案， 不服内蒙古自治区乌海市中级人民法院（2024）内 03 民终 686 号民事判决，向内 蒙古自治区高级人民法院申请再审。现已审查终结。 北京华德申请再审称，请求：1.依法撤销一、二审判决，改判支持北京华德 的全部诉讼请求；2.判令公司、乌海化工承担本案一、二审全部诉讼费。 诉讼进展公告 本公司及董事会全体成员保证信息披露的内容真 ...

Core Viewpoint - Northeast Pharmaceutical (000597) has completed the acquisition of a 70% stake in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. for approximately 187 million yuan, enhancing its capabilities in TCR-T and CAR-T cell therapy technologies and product transformation systems [1] Group 1: Acquisition Details - The acquisition was finalized on November 2024, with a cash payment of about 187 million yuan [1] - The company has gained access to a technology platform and product transformation system in the TCR-T and CAR-T cell therapy fields [1] Group 2: Product Development - Dingcheng Peptide Source's core product, DCTY1102 injection, has received implied approval for clinical trials from the CDE, positioning it to become the second globally and the first domestically targeted KRAS G12D TCR-T cell drug to enter Phase I clinical trials [1] - Another product, DCTY0801, has successfully obtained orphan drug designation from the FDA in the United States [1]

Core Viewpoint - Northeast Pharmaceutical aims to implement a "main business focus, comprehensive industrial expansion" strategy, emphasizing "innovation-driven, digital empowerment, green transformation, and open cooperation" to enhance its competitiveness across the entire industry chain [1] Group 1 - The company plans to transition from a traditional chemical pharmaceutical enterprise to an innovative, international, diversified, and high-quality pharmaceutical health industry group [1] - The strategic focus includes two dimensions: targeting industry high points and horizontal development in the health sector [1]

Group 1: Strategic Planning and Business Model - Northeast Pharmaceutical aims to implement a "main business focus, comprehensive industrial expansion" strategy to enhance profitability and establish a sustainable profit model, maintaining stable growth in line with industry standards [2][3] - The company emphasizes "innovation-driven, digital empowerment, green transformation, and open cooperation" as core strategic directions to build competitive advantages across the entire industry chain [2] Group 2: Impact of Shareholder Changes - After becoming a controlling shareholder in 2018, Fangda Group introduced advanced market-oriented management models, significantly improving Northeast Pharmaceutical's operational efficiency and profitability [4] - The company has shown continuous profit growth over the past five years, indicating resilience and sustainable development capabilities [4] Group 3: Revenue Structure and Future Trends - As of the first three quarters of 2023, the company's revenue structure is stable, with approximately 60% from pharmaceutical manufacturing and 40% from pharmaceutical commerce [6] - Traditional businesses face challenges from industry policies and market competition, while innovative drug segments are expected to drive future growth [6][7] Group 4: Innovation and R&D Developments - The acquisition of a 70% stake in Beijing Dingcheng Peptide Source Biotech Co., Ltd. in 2024 allows Northeast Pharmaceutical to enter the TCR-T and CAR-T cell therapy fields, with promising products already in clinical trials [4][6] - Dingcheng Peptide has established a comprehensive R&D system, focusing on cell and gene therapy, and has received multiple recognitions as a high-tech enterprise [9][10] Group 5: Challenges and Market Dynamics - The company faces challenges in balancing high R&D costs with short-term cash flow pressures, particularly in the competitive cell therapy market [7] - The transition from traditional chemical pharmaceuticals to a dual-driven model of traditional and innovative biopharmaceuticals is critical for future growth [7] Group 6: Talent Acquisition and Team Structure - Dingcheng Peptide's R&D team includes 18 PhDs and 59 master's degree holders, ensuring expertise across key areas of drug development [10] - A recruitment plan aims to onboard 300 master's and doctoral graduates by 2025 to strengthen the R&D capabilities in cell therapy [10]